TORL Bio Raises $96M In Series C Funding, Unveils TORL-1-23
07 Oct 2025 //
PR NEWSWIRE
TORL BioTherapeutics Appoints Anna Berkenblit, MD, MMSc to Board
09 Jun 2025 //
PR NEWSWIRE
TORL BioTherapeutics Appoints Aran Maree CMO, Starts Phase 2 Trial
02 Dec 2024 //
PR NEWSWIRE
TORL BioTherapeutics Shares Phase 1 Results Of TORL-1-23 At ESMO 2024
16 Sep 2024 //
PR NEWSWIRE
TORL BioTherapeutics Appoints Howard "Skip" Burris III
10 Sep 2024 //
PR NEWSWIRE

Market Place
Sourcing Support